Thursday, 15 October 2026European Markets

CONTEXTVISION And VISTIN PHARMA Have A High Dividend Yield And Return On Equity In The Healthcare Sector.

Loading stream...

(VIANEWS) - CONTEXTVISION (CONTX.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.

Financial Asset Price Forward Dividend Yield Return on Equity
CONTEXTVISION (CONTX.OL) kr7.90 3.46% 61.1%
VISTIN PHARMA (VISTN.OL) kr23.90 3.13% 16.03%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. CONTEXTVISION (CONTX.OL)

3.46% Forward Dividend Yield and 61.1% Return On Equity

ContextVision AB (publ), a medical technology software company, provides image analysis and imaging for medical systems in Asia, Europe, and the United States. The company offers image enhancement software for 2D/3D/4D ultrasound, radiography, magnetic resonance imaging (MRI), and veterinary. Its products include Rivent that offers unparalleled image quality for various types of ultrasound systems for women's health, general imaging, cardiovascular, and point of care applications; Rivent Mobile, an enhancing ultrasound image for the handheld ultrasound devices using mobile phones and tablets; and Rivent 3D, an image enhancement product for 3D ultrasound. The company also provides Altumira/Altumira Plus, a platform for digital radiography; and Orthopedic Package for orthopedic imaging. In addition, it offers GOPView MRI2Plus, an image enhancement solution for MRI. The company was founded in 1983 and is headquartered in Stockholm, Sweden.

Earnings Per Share

As for profitability, CONTEXTVISION has a trailing twelve months EPS of kr0.47.

PE Ratio

CONTEXTVISION has a trailing twelve months price to earnings ratio of 16.81. Meaning, the purchaser of the share is investing kr16.81 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 61.1%.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Nov 2, 2023, the estimated forward annual dividend rate is 0.3 and the estimated forward annual dividend yield is 3.46%.

Moving Average

CONTEXTVISION's value is under its 50-day moving average of kr8.37 and below its 200-day moving average of kr8.72.

Volume

Today's last reported volume for CONTEXTVISION is 31152 which is 42.99% below its average volume of 54644.

More news about CONTEXTVISION.

2. VISTIN PHARMA (VISTN.OL)

3.13% Forward Dividend Yield and 16.03% Return On Equity

Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.

PE Ratio

VISTIN PHARMA has a trailing twelve months price to earnings ratio of 23.9. Meaning, the purchaser of the share is investing kr23.9 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.03%.

More news about VISTIN PHARMA.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com